The content on this site is intended for healthcare professionals only
Dr Corey Wayne Speers comments on the LUMINA study findings.
The study showed based on guidance from biomarker screening, patients who are 55 years of age and older with low-grade luminal A-type breast cancer may only need endocrine therapy following breast conserving surgery and could avoid radiation therapy entirely.
Dr Speers also discusses other similar future trials that aim to identify which subgroups of patients may be able to avoid a radiotherapy treatment option.
The patients in the study will continue to be followed for up to 10 years for effects on long term recurrence and survival.
Watch our interview with Dr Whelan here
Watch Dr Whelan's press conference on the study here
Watch Dr Bishal Gyawali comment on the study here
Read our news story about the study here
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
IORT at the Asian Hospital and Medical Center
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
